Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2509-2516

  Ramic, Snježana ^a   Asic, Ksenija ^a   Balja, Melita Peric ^a   Paic, Frane ^b   Benkovic, Vesna ^b   Kneževic, Fabijan ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Breast cancer; HER2; Phosphorylation; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; DRUG EFFICACY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; BREAST TUMOR; DRUG RESISTANCE; FEMALE; HER2; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS;

BREAST CANCER; HER2; PHOSPHORYLATION; TRASTUZUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84881330953     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM and Hayes DF; American Society of Clinical Oncology: College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-125, 2007.
2. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore II D and Thor AD: Relationship of epidermal growth factor receptor expression to ERBB-2 signalling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160, 2005.
3. Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim H-D, Grantcharova V, Lauffenburger DA, and White FM: Effects of HER2 overexpression on cell signalling networks governing proliferation and migration. Mol Syst Biol 2: 54, 2006.
4. Nahta R: Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncology 2012: 428062, 2012.
5. Desmedt C, Sperinde J, Piette F, Huang W, Jin X, Tan Y, Durbecq V, Larsimont D, Giuliani R, Chappey C, Buyse M, Winslow J, Piccart M, Sotiriou C, Petropoulos C and Bates M: Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 18(1): 22-29, 2009.
6. Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C and Winslow J: A novel proximity assay for the detection of proteins and protein complexes: Quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffinembedded cell lines and breast cancer tissue. Diagn Mol Pathol 18(1): 11-21, 2009.
7. Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, John JT and Bartlett MS: In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrate prognostic significance in early breast cancer. Breast Cancer Res Treat 132(2): 463-470, 2012.
8. Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S: Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 42: 636-645, 2006.
9. Taniyama K, Ishida K, Toda X, Motoshita J, Kuraoka K, Saito A, Tni Y, Uike T, Teramoto S and Koseki M: Tyrosine 1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. Breast Cancer 15(3): 231-240, 2008.
10. DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD and Stern DF: Active signaling by Neu in transgenic mice. Oncogene 17: 1877-1884, 1998.
11. Bates M, Sperinde J, Leitzel K, Koestler W, Fuchs E, Ali S, Weidler J, Wu Y, DeFazio-Eli L, Frankson K, Winslow J, Chappey C, Huang W and Lipton A: Quantitative HER2 homodimer levels correlate with time to first recurrence in HER2-positive breast cancer patients who did not receive trastuzumab in the adjuvant setting. Cancer Res 69(2 Suppl): SABCS-1074, 2009.
12. Bates M, Sperinde J, Kostler WJ, Ali SM, Leitzel K, Fuchs EM, Paquet A, Lie Y, Sherwood T, Horvat R, Singer CF, Winslow J, Weidler JM, Huang W and Lipton A: Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol 22: 2014-2020, 2011.
13. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L and Winslow J: Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: Applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res 13: R44, 2011.
14. DiGiovanna MP, Carter D, Flynn SD and Stern DF: Functional assay for HER-2/neu demonstrate active signaling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 74: 802-806, 1996.
15. Thor AD, Liuv S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF and DiGiovanna MP: Activation (tyrosine phosphorylation) of ERBB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18: 3230-3239, 2000.
16. Hudelist G, Kostler WJ, Czerwenka K, Kubista E, Attems J, Muller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschutzky H, Zielinski CC, Singer CF: HER2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumabbased therapy in patients with metastatic breast cancer. Int J Cancer 118: 1126-1134, 2006.
17. Hudis CA: Trastuzumab -mechanism of action and use in clinical practice. N Eng J Med 357: 39-51, 2007.
18. Dean-Colomb W and Esteva FJ: HER2-positive breast cancer: Herceptin and beyond. Eur J Cancer 44(18): 2806-2812, 2008.
19. Fiszman GL and Jasnis MA: Molecular mechanisms of trastuzumab resistance in HER2-overexpressing breast cancer. Int J Breast Cancer 2011: 352182, 2011.
20. Ross JS, Slodkowska EA, Symmans WF, Puszal L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER2 therapy and personalized medicine. Oncologist 14: 320-368, 2009.
21. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, Gonzalez-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M and Arteaga CL: Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71(5): 1871-1882, 2011.
22. Ginestier C, Adelaide J, Goncalves A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P and Birnbaum D. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26: 7163-7169, 2007.
23. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN and Ueno NT: Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist 16(7): 956-965, 2011.
24. Wulfkuhle J, Pierobon M, Laird J, Espina V, Liotta L, Esserman L, Petricoin E: Discovery of a new phospho-HER2+/FISH-molecular subtype of human breast cancer by functional pathway mapping. J Clin Oncol 27: 15s, 2009.
25. Menendez JA, Mehmi I and Lupu R: Trastuzumab in combination with heregulin-Activated HER-2/neu (ERBB2) triggers a receptor-enhanced chemosensitivity effect in the absence of HER2/neu overexpression. J Clin Oncol 24: 3735-3746, 2006.
26. Arteaga CL: Can trastuzumab be effective against tumors with low HER2/Neu (ERBB2) receptors? J Clin Oncol 24(23): 3722-3725, 2006.
27. Frogne C, Laenkholm AV, Lyng MB, Henriksen KL and Lykkesfeldt AE: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 11: 1186-1200, 2009.
28. DiGiovanna MP, Chu P, Davison TL, Davidson TL, Howe CL, Carter D, Claus EB and Stern D: Active signaling by HER-2 in a subpopulation of HER-2-overexpressing ductal carcinoma in situ: Clinicopathological correlates. Cancer Res 62: 6667-6673, 2002.
29. Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF: HER-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89: 983-991, 2003.
30. Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B and Kong A: HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 Herceptin in breast cancer. PLoS Biol 8(12): e1000563, 2010.
31. Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ and Cardoso F: Phosphorylated HER-2 tyrosine kinase and HER-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2-overexpressing metastatic breast cancer. Eur J Cancer 43: 725-735, 2007.